The Hydrus Microstent is an innovative canal-based, minimally invasive glaucoma surgery (MIGS) device for patients with mild-to-moderate primary open-angle glaucoma.
This device is the only MIGS implant to span approximately 90° of Schlemm’s canal, ensuring access to collector channels in the nasal region.1-3 The first MIGS device to precisely dilate and scaffold Schlemm’s canal, it gently expands the cross sectional area without obstructing outflow access to collector channel ostia.1-3 The Hydrus Microstent bypasses the trabecular meshwork to restore flow of aqueous from the anterior chamber through the inlet of the microstent into Schlemm’s canal.1
The Hydrus Microstent comes preloaded in a single-use hand-held delivery system featuring: 1) A tracking wheel for controlled delivery, 2) A rotatable cannula ensuring positioning and alignment for a range of hand positions, and 3) A cannula tip designed to match curvature of the trabecular meshwork.
Hydrus is the first and only MIGS device to report clinical outcomes from a pivotal trial with five years of continuous follow-up – achieving 80% retention at year five.4 The long-term results show that 59% of Hydrus patients remained medication-free at five years.5
Contact: Alcon Account Manager Please refer to product direction for use for list of indications, contraindications and warnings.
References
- Hydrus Microstent instructions for use.
- Samuelson TW, et al. doi: 10.1016/j.ophtha.2018.05.012.
- Market Scope 2021, Glaucoma surgical device market report: 2020-2026. July 2021.
- Ahmed IIK, De Francesco T, Singh K, et al. doi:10.1016/j.ophtha.2022.02.021
- Alcon data on file, 2024.
